The widespread clinical application of islet transplantation is limited by the shortage of human islet donors, and the harmful side effects and potential health risks of long-term use of conventional immunosuppressive drugs. The major areas of research in my laboratory are (i) elucidation of the mechanism of islet graft rejection and (ii) development of safer therapy in preventing rejection of islet grafts. Specifically, I am examining the interactions of T cells and innate immune cells that lead to the rejection of pig islets in individuals with and without autoimmune type 1 diabetes. I am also examining how short-term administration of monoclonal antibodies can protect the pig islets after transplantation. My work will help to bring to fruition the clinical application of pig islet transplantation without the continuous use of immunosuppressive drugs, and thus make this therapy widely available for patients especially children with type 1 diabetes.